Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Array BioPharma Inc.
Array BioPharma’s ARRY-520 Demonstrates Significant Activity in Hematological and Taxane-Resistant Tumors
May 12th, 2009
Array BioPharma Inc. (NASDAQ: ARRY) announced the presentation of two abstracts detailing positive preclinical data for its novel kinesin spindle protein (KSP) inhibitor, ARRY-520. The abstracts and an oral educational session, which were presented at the American Association for Cancer Research (AACR) 100th Annual Meeting, suggest that ARRY-520 may be a promising therapy for the treatment of hematological and taxane-resistant malignancies. ARRY-520 is a highly potent, selective KSP inhibitor currently in a Phase 1 trial for solid tumors and Phase 1/2 trials for multiple myeloma and acute myelogenous leukemia (AML). The complete presentations are available as PDFs on Array's website at...
Source: Cancer Weekly (2009-05-12)
|
